Timo A Auer1, Hanns-Christian Breit2, Federico Marini3, Mirjam Renovanz4, Florian Ringel4, Clemens J Sommer5, Marc A Brockmann2, Yasemin Tanyildizi6. 1. University Medical Center, Department of Neuroradiology, Johannes Gutenberg-University Mainz, Langenbeckstr. 1, 55131 Mainz, Germany; University Medical Center-Charité, Department of Radiology, Berlin, Germany. 2. University Medical Center, Department of Neuroradiology, Johannes Gutenberg-University Mainz, Langenbeckstr. 1, 55131 Mainz, Germany. 3. University Medical Center, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), Mainz, Germany. 4. University Medical Center, Department of Neurosurgery, Mainz, Germany. 5. Institute of Neuropathology, University Medical Center Mainz, Germany. 6. University Medical Center, Department of Neuroradiology, Johannes Gutenberg-University Mainz, Langenbeckstr. 1, 55131 Mainz, Germany. Electronic address: y.tanyildizi@gmx.net.
Abstract
BACKGROUND: Response Assessment in Neuro-Oncology Criteria (RANO), are used to asses response to first-line treatment of glioblastoma (GBM). Differentiation between response and pseudoresponse under treatment with Bevacizumab (BVZ) remains challenging. This study evaluates ADC changes in patients with radiographic pseudoresponse under treatment with (BVZ). METHODS: Patients (n=40) with recurrent GBM under-treatment with BVZ underwent MRI before, two and four months after treatment with BVZ. In patients with radiological pseudoresponse (n=11), ADC analyses were performed. Areas with decreasing T1 contrast enhancement (CE) and FLAIR signal decrease were manually selected and compared to size and position matched healthy contralateral brain parenchyma. RESULTS: Histogram based ADC (10-6×mm2/s) of these patients decreased significantly (P<0.005) from baseline MRI (T1-CE, FLAIR: 1124.9±160.3, 1098.4±226.2, respectively) to 2months (781.3±110.7, 783.3±103.3) and remained stable during 4months (777.0±138.5, 784.4±155.4, all mean±1 SD), despite progressive disease. Mean ADC values of the healthy contralateral brain tissue remained stable (P>0.05) (ADC values: baseline: 786.2±110.7, 2months: 781.1±76.2, 4months: 804.1±86.2). CONCLUSION: Treatment of GBM with BVZ leads to a decrease of ADC values in areas of pre-treatment T1-CE/FLAIR signal hyperintensity to levels of comparable with normal brain tissue. ADC values remained stable, even when progressive tumor growth was reported.
BACKGROUND: Response Assessment in Neuro-Oncology Criteria (RANO), are used to asses response to first-line treatment of glioblastoma (GBM). Differentiation between response and pseudoresponse under treatment with Bevacizumab (BVZ) remains challenging. This study evaluates ADC changes in patients with radiographic pseudoresponse under treatment with (BVZ). METHODS:Patients (n=40) with recurrent GBM under-treatment with BVZ underwent MRI before, two and four months after treatment with BVZ. In patients with radiological pseudoresponse (n=11), ADC analyses were performed. Areas with decreasing T1 contrast enhancement (CE) and FLAIR signal decrease were manually selected and compared to size and position matched healthy contralateral brain parenchyma. RESULTS: Histogram based ADC (10-6×mm2/s) of these patients decreased significantly (P<0.005) from baseline MRI (T1-CE, FLAIR: 1124.9±160.3, 1098.4±226.2, respectively) to 2months (781.3±110.7, 783.3±103.3) and remained stable during 4months (777.0±138.5, 784.4±155.4, all mean±1 SD), despite progressive disease. Mean ADC values of the healthy contralateral brain tissue remained stable (P>0.05) (ADC values: baseline: 786.2±110.7, 2months: 781.1±76.2, 4months: 804.1±86.2). CONCLUSION: Treatment of GBM with BVZ leads to a decrease of ADC values in areas of pre-treatment T1-CE/FLAIR signal hyperintensity to levels of comparable with normal brain tissue. ADC values remained stable, even when progressive tumor growth was reported.
Authors: Giuseppe Lombardi; Alessandro Spimpolo; Sara Berti; Cristina Campi; Maria Giulia Anglani; Rossella Simeone; Laura Evangelista; Francesco Causin; Giovanni Zorzi; Giancarlo Gorgoni; Mario Caccese; Marta Padovan; Vittorina Zagonel; Diego Cecchin Journal: Br J Radiol Date: 2021-11-23 Impact factor: 3.039